THE 60-SECOND GUIDE
Octreotide
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Octreotide mimics somatostatin, a hormone that restrains several other hormones and digestive secretions. Its established uses include selected patients with acromegaly and control of severe diarrhea or flushing in particular hormone-secreting tumor syndromes. It does not simply reset all hormones. [1]
Potential benefits
Suppresses selected hormone and gastrointestinal secretions. Has established uses in acromegaly and certain neuroendocrine settings. [1]
Evidence & its limits
Suppressing secretions has trade-offs: gallstones, altered blood glucose, gastrointestinal problems, and cardiac conduction effects can occur. Symptom control in a hormone-secreting tumor is a different outcome from curing the underlying cancer. [1]
Risks & unknowns
Gastrointestinal symptoms, gallstones, glucose changes, and cardiac effects can occur. It is not a universal hormone-balancing treatment. [1]
Status & scope
Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA Drugs@FDA database
- MedlinePlus: medication-specific uses and precautions
- SANDOSTATIN injection prescribing information
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.